• 1
    Musial J, Rys D, Brozek J, Swadzba J, Iwaniec T. More on: fluvastatin inhibits upregulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2005; 3: 6145.DOI: 10.1111/j.1538-7836.2005.01200.x
  • 2
    Ferrara DE, Swerlick R, Casper K, Meroni PL, Vega-Ostertag ME, Harris EN, Pierangeli S. Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. J Thromb Haemost 2004; 2: 155863.DOI: 10.1111/j.1538-7836.2004.00896.x
  • 3
    Meroni PL, Raschi E, Testoni C, Tincani A, Balestrieri G, Molteni R, Khamashta MA, Tremoli E, Camera M. Statins prevent endothelial cell activation induced by antiphospholipid (anti-β2glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype. Arthritis Rheum 2001; 44: 28708.DOI: 10.1002/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y
  • 4
    Ferrara DE, Liu X, Espinola RG, Meroni PL, Abukhalaf I, Harris EN, Pierangeli SS. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48: 32729.DOI: 10.1002/art.11449
  • 5
    Undas A, Celiska-Lowenhoff M, Kaczor M, Musial J. New nonlipid effects of statins and their clinical relevance in cardiovascular disease. Review article. Thromb Haemost 2004; 91: 106577.
  • 6
    Krysiak R, Okopien B, Herman ZS. Effects of HMG-CoA Reductase inhibitors on coagulation and fibrinolysis processes. Review article. Drugs 2003; 63: 182154.
  • 7
    Undas A, Brummel-Ziedins E, Mann KG. Statins and blood coagulation. Arterioscler Thromb Vasc Biol 2005; 25: 18.
  • 8
    Musial J, Swadzba J, Jankowski M, Grzywacz M, Bazan-Socha S, Szczeklik A. Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid-protein antibodies. Thromb Haemost 1997; 78: 11737.
  • 9
    Martinuzzo ME, Forastiero RR, Kordich L, Carreras LO. Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies. Br J Haematol 2001; 114: 84551.DOI: 10.1046/j.1365-2141.2001.03028.x
  • 10
    Williams FM, Parmar K, Hughes GR, Hunt BJ. Systemic endothelial cell markers in primary antiphospholipid syndrome. Thromb Haemost 2000; 84: 7426.
  • 11
    Kaplanski G, Cacoub P, Farnarier C, Marin V, Gregoire R, Gatel A, Durand JM, Harle JR, Bongrand P, Piette JC. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with severity of thrombosis. Arthritis Rheum 2000; 43: 5564.DOI: 10.1002/1529-0131(200001)43:1<55::AID-ANR8>3.0.CO;2-M
  • 12
    Amengual O, Atsumi T, Khamashta MA, Hughes GRV. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 1998; 79: 27681.
  • 13
    Szczeklik A, Musial J, Undas A, Gajewski P, Gora P, Swadzba J, Jankowski M. Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. Am Coll Cardiol 1999; 33: 128693.DOI: 10.1016/S0735-1097(99)00023-6